ReproCELL Inc. (JP:4978)

:4978

4978

ReproCELL Inc.

RESEARCH TOOLSreports

Want to see JP:4978 full AI Analyst Report?

ReproCELL Inc. (4978) Price & Analysis

0 Followers

4978 Stock Chart & Stats

¥143.00

¥3.00(2.91%)

At close: Jan 08 4:00 PM EST

¥143.00

¥3.00(2.91%)

Day’s Range― - ―

52-Week Range¥138.00 - ¥242.00

Previous CloseN/A

Volume331.50K

Average Volume (3M)510.74K

Market Cap

¥16.07B

Enterprise Value¥13.40B

Total Cash (Recent Filing)¥4.72B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta0.60

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding95,147,890

10 Day Avg. Volume504,660

30 Day Avg. Volume510,736

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)1.88

Price to Sales (P/S)7.46

P/FCF Ratio-34.60

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet Strength (no Debt)ReproCELL's virtually debt-free balance sheet and sizable equity buffer give it durable financial flexibility. This reduces default risk, supports continued R&D and service delivery during revenue troughs, and provides runway to fund strategic initiatives without immediate refinancing.

Solid Gross Profit BaseSustained gross profit above ¥1.0B indicates an underlying margin on products and services. That absolute profit pool supports scalability: if operating costs are controlled, incremental revenue can flow to the bottom line, enabling durable margin recovery when sales stabilize.

Exposure To IPSC And Regenerative Medicine DemandReproCELL operates in structurally growing research tools and regenerative medicine markets. Its iPSC product/service focus targets long-term secular demand from drug discovery and disease modeling, supporting recurring contract work and product sales across academic and pharma customers.

Bears Say

Persistent Negative Free Cash FlowConsistent negative operating and free cash flow means the business does not self-fund growth or cover cyclical shortfalls. Over months this pressures liquidity, forces external financing or equity raises, and constrains reinvestment in product development or scaling of contract services.

Volatile And Declining RevenueLarge swings and recent revenue declines undermine predictability and limit the company's ability to plan R&D or staffing. Structural revenue volatility raises customer concentration and execution risks, reducing visibility for sustainable margin improvement over coming quarters.

Inconsistent Profitability And ReturnsFrequent swings between brief profit and sizable losses indicate underlying issues converting revenue to durable earnings. This pattern questions operational efficiency and management execution, making future profitability reliant on structural cost or revenue fixes rather than near-term cyclical improvements.

4978 FAQ

What was ReproCELL Inc.’s price range in the past 12 months?

ReproCELL Inc. lowest stock price was ¥138.00 and its highest was ¥242.00 in the past 12 months.

What is ReproCELL Inc.’s market cap?

ReproCELL Inc.’s market cap is ¥16.07B.

When is ReproCELL Inc.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were ReproCELL Inc.’s earnings last quarter?

Currently, no data Available

Is ReproCELL Inc. overvalued?

According to Wall Street analysts ReproCELL Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does ReproCELL Inc. pay dividends?

ReproCELL Inc. does not currently pay dividends.

What is ReproCELL Inc.’s EPS estimate?

ReproCELL Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does ReproCELL Inc. have?

ReproCELL Inc. has 95,147,890 shares outstanding.

What happened to ReproCELL Inc.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of ReproCELL Inc.?

Currently, no hedge funds are holding shares in JP:4978

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

ReproCELL Inc.

ReproCELL Incorporated operates as a stem cell research company in Japan. It offers stem cell reagents, including RNA reprogramming, small molecules, growth factors and cytokines, antibodies and staining kits, pluripotent stem cell culture media, cell substrates, cryopreservation media, dissociation solution, and transfection reagents; differentiated induced pluripotent stem cell (iPSC) and related reagents, feeder cells, and induced neurons; and 3D cell culture; and labware. The company also provides preclinical genomics, stem cell research, drug efficacy, safety, & ADME, human tissue samples, therapeutic pipeline, clinical laboratory services, clinical diagnostic services, and gmp ipsc master cell bank services. ReproCELL Incorporated was incorporated in 2003 and is based in Yokohama, Japan.